A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Inclusion Criteria:

1. Has moderately to severely active CD with a BWT of >3 mm, based on IUS performedwithin the previous 4 weeks from baseline.

2. Newly initiating IV vedolizumab induction treatment in accordance with the currentSmPC either at enrolment or within 2 weeks after enrolment (switch to SC isacceptable at maintenance treatment stage).

Exclusion Criteria:

1. Prior history of intolerability, hypersensitivity to the active substance or to anyof the excipients of vedolizumab.

2. Active severe infections such as tuberculosis (TB), sepsis, cytomegalovirus,listeriosis, and opportunistic infections such as Progressive MultifocalLeukoencephalopathy (PML).

3. Cognitive incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.

4. Current or previous participation in an interventional clinical trial for CD withinthe past 30 days, or planned to be enrolled in an interventional clinical trial forCD.

5. Ongoing or planned pregnancy or breastfeeding participants.

6. Active perforating complications or significant current strictures (assessed by IUS,with or without pre-stenotic dilatation) as per clinical judgement.

7. Characteristics precluding IUS visualization of affected bowel segments or normalBWT of <=3 mm for all segments.